Literature DB >> 7561674

Expression of HLA-C molecules confers target cell resistance to some non-major histocompatibility complex-restricted T cells in a manner analogous to allospecific natural killer cells.

C S Falk1, A Steinle, D J Schendel.   

Abstract

Specific HLA molecules have recently been shown to confer target cell resistance to lysis by some CD3- natural killer (NK) cells. For certain NK clones, resistance is governed by two specificities (NK1 and NK2) that are associated with particular HLA-C alleles: in general, target cells expressing Cw1, Cw3, Cw7, or Cw8 are susceptible to NK1 but resistant to NK2 clones, whereas target cells expressing Cw2, Cw4, Cw5, or Cw6 are susceptible to NK2 and resistant to NK1 cells. These two clusters of HLA-C alleles are distinguished by a dimorphism in the alpha 1 helical region, localized at amino acid positions 77 and 80. In this report, we show that highly enriched CD3+/CD56- cytotoxic T cell sublines and CD3-/CD56+ NK sublines derived from the same donor have identical cytolytic specificities when tested against a panel of allogeneic LCL and various HLA-B and -C transfectant cell lines. The lysis pattern of the allogeneic cells appeared to be related to the NK2 specificity for both effector cells: LCL expressing HLA-Cw2, Cw4, Cw5, or Cw6 alleles were lysed, while LCL expressing HLA-Cw1, Cw3, or Cw7 molecules were resistant. Resistance to lysis could be conferred to susceptible target cells by transfection with a Cw*0702 gene, while expression of a Cw*0602 gene did not provide protection. Similar patterns of HLA-C-mediated resistance were also found with two polyclonal T cell lines generated from the peripheral blood lymphocytes of unrelated donors. Thus, major histocompatibility complex (MHC) molecules that induced resistance to particular NK cells also regulated target cell resistance to lysis by these non-MHC-restricted effector T cells. For both types of effector cells, direct binding to HLA-C molecules was necessary to achieve inhibition since preincubation with mAb specific for class I molecules destroyed the protection from lysis of HLA-Cw7 expressing target cells. mAbs specific for CD3 and CD8 molecules had no influence on lysis or inhibition of the NK-like T cells. Formation of MHC complexes with particular peptides did not appear to be essential to confer resistance, since a cell line with defective peptide transporter genes (TAP genes), when transfected with an appropriate HLA-C allele, was as resistant to lysis as HLA-C transfectant lines with normal TAP function. These results suggest that HLA-C molecules may deliver negative regulatory signals to some non-MHC-restricted T cells in a manner similar to that described previously for particular NK cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7561674      PMCID: PMC2192283          DOI: 10.1084/jem.182.4.1005

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  55 in total

1.  Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes.

Authors:  W J Storkus; J Alexander; J A Payne; J R Dawson; P Cresswell
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

2.  HLA-JY328: mapping studies and expression of a polymorphic HLA class I gene.

Authors:  B W Duceman; D Ness; R Rende; M J Chorney; R Srivastava; D S Greenspan; J Pan; S M Weissman; F C Grumet
Journal:  Immunogenetics       Date:  1986       Impact factor: 2.846

3.  Production of human cells expressing individual transferred HLA-A,-B,-C genes using an HLA-A,-B,-C null human cell line.

Authors:  Y Shimizu; R DeMars
Journal:  J Immunol       Date:  1989-05-01       Impact factor: 5.422

4.  YAC-1 MHC class I variants reveal an association between decreased NK sensitivity and increased H-2 expression after interferon treatment or in vivo passage.

Authors:  G E Piontek; K Taniguchi; H G Ljunggren; A Grönberg; R Kiessling; G Klein; K Kärre
Journal:  J Immunol       Date:  1985-12       Impact factor: 5.422

5.  Organization, sequence and expression of the HLA-B27 gene: a molecular approach to analyze HLA and disease associations.

Authors:  E H Weiss; W Kuon; C Dörner; M Lang; G Riethmüller
Journal:  Immunobiology       Date:  1985-12       Impact factor: 3.144

6.  Standardization of the human in vitro cell-mediated lympholysis technique.

Authors:  D J Schendel; R Wank; B Dupont
Journal:  Tissue Antigens       Date:  1979-02

7.  Alloantigen recognition by two human natural killer cell clones is associated with HLA-C or a closely linked gene.

Authors:  M Colonna; T Spies; J L Strominger; E Ciccone; A Moretta; L Moretta; D Pende; O Viale
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-01       Impact factor: 11.205

8.  Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy.

Authors:  K Kärre; H G Ljunggren; G Piontek; R Kiessling
Journal:  Nature       Date:  1986 Feb 20-26       Impact factor: 49.962

9.  Production of human T cell growth factor.

Authors:  D J Schendel; R Wank
Journal:  Hum Immunol       Date:  1981-07       Impact factor: 2.850

10.  Impaired assembly and transport of HLA-A and -B antigens in a mutant TxB cell hybrid.

Authors:  R D Salter; P Cresswell
Journal:  EMBO J       Date:  1986-05       Impact factor: 11.598

View more
  8 in total

Review 1.  HLA-C revisited. Ten years of change.

Authors:  C S Falk; D J Schendel
Journal:  Immunol Res       Date:  1997       Impact factor: 2.829

Review 2.  Cell-based vaccines for renal cell carcinoma: genetically-engineered tumor cells and monocyte-derived dendritic cells.

Authors:  Bernhard Frankenberger; Sybille Regn; Christiane Geiger; Elfriede Noessner; Christine S Falk; Heike Pohla; Miran Javorovic; Tobias Silberzahn; Susanne Wilde; Alexander Buchner; Michael Siebels; Ralph Oberneder; Gerald Willimsky; Antonio Pezzutto; Thomas Blankenstein; Dolores J Schendel
Journal:  World J Urol       Date:  2005-07-05       Impact factor: 4.226

3.  The direct binding of a p58 killer cell inhibitory receptor to human histocompatibility leukocyte antigen (HLA)-Cw4 exhibits peptide selectivity.

Authors:  S Rajagopalan; E O Long
Journal:  J Exp Med       Date:  1997-04-21       Impact factor: 14.307

4.  Requirements for CD1d recognition by human invariant Valpha24+ CD4-CD8- T cells.

Authors:  M Exley; J Garcia; S P Balk; S Porcelli
Journal:  J Exp Med       Date:  1997-07-07       Impact factor: 14.307

5.  Uptake of CCR7 by KIR2DS4⁺ NK cells is induced upon recognition of certain HLA-C alleles.

Authors:  Silvia Pesce; Simona Carlomagno; Alessandro Moretta; Simona Sivori; Emanuela Marcenaro
Journal:  J Immunol Res       Date:  2015-04-16       Impact factor: 4.818

6.  Presentation of an immunodominant immediate-early CD8+ T cell epitope resists human cytomegalovirus immunoevasion.

Authors:  Stefanie Ameres; Josef Mautner; Fabian Schlott; Michael Neuenhahn; Dirk H Busch; Bodo Plachter; Andreas Moosmann
Journal:  PLoS Pathog       Date:  2013-05-23       Impact factor: 6.823

7.  Major histocompatibility complex class I molecules modulate activation threshold and early signaling of T cell antigen receptor-gamma/delta stimulated by nonpeptidic ligands.

Authors:  I Carena; A Shamshiev; A Donda; M Colonna; G D Libero
Journal:  J Exp Med       Date:  1997-11-17       Impact factor: 14.307

Review 8.  HLA-dependent tumour development: a role for tumour associate macrophages?

Authors:  Maddalena Marchesi; Emilia Andersson; Lisa Villabona; Barbara Seliger; Andreas Lundqvist; Rolf Kiessling; Giuseppe V Masucci
Journal:  J Transl Med       Date:  2013-10-06       Impact factor: 5.531

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.